CHM 0.00% 1.4¢ chimeric therapeutics limited

Stunning presentation. Looks like massive delays with the GBM...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,536 Posts.
    lightbulb Created with Sketch. 510
    Stunning presentation.

    Looks like massive delays with the GBM trial. Reworking the whole design to include IV delivery for first dose and adding in chemo.

    Disappointed we won't see any further GBM results for a long time (probably 2026), especially since the data to date has been so compelling.

    CDH17 now officially the lead candidate. The cohort patient numbers are not at all clear. I take it 15 patients is all dose escalation. And then dose expansion - will they make up the phase 2 patient numbers?
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.